Draft monograph: Pramlintide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Every contributing trial shares one sponsor and the monograph does not say so — arising from DRAFT-PRAMLINTIDE-/001. Sponsor concentration is now stated with the certainty rating, and the monograph records how many independent sponsors contributed evidence to each assessed outcome.
2. Trials are described as terminated where they completed as planned — arising from DRAFT-PRAMLINTIDE-/003. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
3. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-PRAMLINTIDE-/004. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
4. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-PRAMLINTIDE-/005. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
5. The search date is not on the face of the document — arising from DRAFT-PRAMLINTIDE-/006. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
6. Local reactions are omitted from the adverse-event table because the trials reported them separately — arising from DRAFT-PRAMLINTIDE-/007. Local reactions are now carried in the adverse-event table wherever the source trials report them, footnoted with the convention each trial used.
7. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-PRAMLINTIDE-/008. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
8. Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-PRAMLINTIDE-/009. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
9. What happens when the compound is stopped is not addressed — arising from DRAFT-PRAMLINTIDE-/010. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
10. The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-PRAMLINTIDE-/011. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.
11. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-PRAMLINTIDE-/012. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
12. The interaction section lists mechanisms rather than interactions — arising from DRAFT-PRAMLINTIDE-/013. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
13. The route of administration studied is not the route in which the compound is supplied — arising from DRAFT-PRAMLINTIDE-/015. The assessed-outcome table now carries the studied route in every row, and a standing note appears wherever the supplied presentation differs from it.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.